학술논문
A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020
Document Type
article
Author
Ignacio J. Ansotegui; Giovanni Melioli; Giorgio Walter Canonica; R. Maximiliano Gómez; Erika Jensen-Jarolim; Motohiro Ebisawa; Olga Luengo; Luis Caraballo; Giovanni Passalacqua; Lars K. Poulsen; Eleonora Savi; Torsten Zuberbier; Elisa Villa; John Oppenheimer; Riccardo Asero; Jonathan Bernstein; Jean Bousquet; Victoria Cardona; Lindo Cox; Pascal Demoly; Fatima Ferreira; Pedro Giavina Bianchi; Sandra Gonzalez Diaz; Thilo Jakob; Luciana Kase Tanno; Jorg Kleine-Tebbe; Michael Levin; Bryan Martin; Paolo Maria Matricardi; Olga Patricia Monge Ortega; Mario Morais Almeida; Carlos Nunes; José Antonio Ortega Martell; Harald Renz; Nelson Rosário Filho; Philip Rouadi; Alessia Ruiba; Hugh Sampson; Mario Sánchez Borges; Enrico Scala; Peter Schmid-Grendelmeier; Gian-Enrico Senna; Juan Carlos Sisul; Mimi L.K. Tang; Rudolf Valenta; Marianne van Hage; Gary W.K. Wong; Anahí Yáñez
Source
World Allergy Organization Journal, Vol 13, Iss 2, Pp - (2020)
Subject
Language
English
ISSN
1939-4551
Abstract
Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@.PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies. Keywords: Diagnosis, Molecular allergy, Cross reactivity, Panallergen, Specific IgE, PAMD@